Literature DB >> 27509991

AgeStandardized Incidence Rates and Survival of Osteosarcoma in Northern Thailand.

Dumnoensun Pruksakorn1, Areerak Phanphaisarn, Donsuk Pongnikorn, Karnchana Daoprasert, Pimpisa Teeyakasem, Parunya Chaiyawat, Narisara Katruang, Jongkolnee Settakorn.   

Abstract

Osteosarcoma is a common primary malignant bone tumor in children and adolescents. Recent worldwide average incidences of osteosarcoma in people aged 0 to 24 years were 4.3 and 3.4 per million, respectively, with a ratio of 1.4:1. However, data on the incidence of osteosarcoma in Thailand are limited. This study analyzed the incidence of osteosarcoma in the upper northern region of Thailand, with a population of 5.85 million people (8.9% of the total Thai population), using data for the years 1998 to 2012, obtained from the Chiang Mai Cancer Registry (CMCR) at Chiang Mai University Hospital and the Lampang Cancer Registry (LCR) at the Lampang Cancer Hospital, a total of 144 cases. The overall annual incidence of osteosarcoma was 1.67 per million with a male:female ratio of 1.36:1. Incidences by age group (male and female) at 0 to 24, 25 to 59 and over 60 years were 3.5 (3.9 and 3.0), 0.8 (0.9 and 0.6), and 0.7 (0.8 and 0.5), respectively. The peak incidence occurred at 15 to 19 years for males and at 10 to 14 years for females. The median survival time was 18 months with a 5year survival rate of 43%. Neither the age group nor the 5year interval period of treatment was significantly correlated with survival during the 15year period studied.

Entities:  

Mesh:

Year:  2016        PMID: 27509991

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  10 in total

1.  IMPDH2 and HPRT expression and a prognostic significance in preoperative and postoperative patients with osteosarcoma.

Authors:  Parunya Chaiyawat; Areerak Phanphaisarn; Nutnicha Sirikaew; Jeerawan Klangjorhor; Viraporn Thepbundit; Pimpisa Teeyakasem; Phichayut Phinyo; Dumnoensun Pruksakorn; Jongkolnee Settakorn
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

2.  Predictors and Treatment Outcomes of Pediatric Osteosarcoma in Diverse Socioeconomic Backgrounds in Southeast Asia: A Retrospective Multicenter Study.

Authors:  Chalinee Monsereenusorn; Ana Patricia Alcasabas; Amos Hong Pheng Loh; Shui Yen Soh; Kenneth Wong Pak Leung; Chetan Dhamne; Sally Blair; Catherine Lam; Piya Rujkijyanont; Chanchai Traivaree; Apichat Photia; Puwadon Veerapan; Mark E Puhaindran; Bernice L Z Oh; Edward Wang; Carlos Rodriguez-Galindo
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

3.  Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome.

Authors:  Kuo Sun; Qi Liao; Zenggan Chen; Tongyi Chen; Jian Zhang
Journal:  Oncol Lett       Date:  2018-07-31       Impact factor: 2.967

4.  Knockdown of KCNQ1OT1 Suppresses Cell Invasion and Sensitizes Osteosarcoma Cells to CDDP by Upregulating DNMT1-Mediated Kcnq1 Expression.

Authors:  Xu Qi; Xiao-Jun Yu; Xu-Ming Wang; Tie-Nan Song; Jie Zhang; Xin-Zhen Guo; Guo-Jun Li; Ming Shao
Journal:  Mol Ther Nucleic Acids       Date:  2019-06-27       Impact factor: 8.886

5.  miR-522-3p Promotes Osteosarcoma Cell Growth By Regulating Glucose Uptake And GLUT1 Expression.

Authors:  Rong Chen; Jiasheng Lin; Wei Yan; Dongdong Chen
Journal:  Onco Targets Ther       Date:  2019-11-01       Impact factor: 4.147

6.  Anal extraskeletal osteosarcoma in a man: a case report and review of the literature.

Authors:  Ramin Saadaat; Jamshid Abdul-Ghafar; Nasir Ud Din; Ahmed Maseh Haidary
Journal:  J Med Case Rep       Date:  2020-04-20

7.  Curcumol Synergizes with Cisplatin in Osteosarcoma by Inhibiting M2-like Polarization of Tumor-Associated Macrophages.

Authors:  Jincheng Wang; Jialu Jin; Ting Chen; Qian Zhou
Journal:  Molecules       Date:  2022-07-06       Impact factor: 4.927

8.  SLC25A22 Promotes Proliferation and Metastasis of Osteosarcoma Cells via the PTEN Signaling Pathway.

Authors:  Ming-Wei Chen; Xue-Jian Wu
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

9.  Clinical and radiographic presentation of pelvic sarcoma in children.

Authors:  Muayad Kadhim; Nariman Abol Oyoun; Richard B Womer; John P Dormans
Journal:  SICOT J       Date:  2018-10-19

10.  Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial.

Authors:  Nut Koonrungsesomboon; Nuttapong Ngamphaiboon; Natavudh Townamchai; Pimpisa Teeyakasem; Chaiyut Charoentum; Pimlak Charoenkwan; Rungrote Natesirinilkul; Lalita Sathitsamitphong; Touch Ativitavas; Parunya Chaiyawat; Jeerawan Klangjorhor; Suradej Hongeng; Dumnoensun Pruksakorn
Journal:  BMC Cancer       Date:  2020-03-30       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.